LPL Financial LLC Increases Stock Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

LPL Financial LLC increased its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 8.0% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 20,366 shares of the company’s stock after purchasing an additional 1,510 shares during the quarter. LPL Financial LLC’s holdings in Amphastar Pharmaceuticals were worth $756,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the business. TD Private Client Wealth LLC lifted its holdings in shares of Amphastar Pharmaceuticals by 22.7% during the 4th quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company’s stock worth $78,000 after acquiring an additional 388 shares during the period. Smartleaf Asset Management LLC raised its stake in Amphastar Pharmaceuticals by 222.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock worth $26,000 after purchasing an additional 493 shares during the period. KBC Group NV boosted its holdings in shares of Amphastar Pharmaceuticals by 43.1% in the 4th quarter. KBC Group NV now owns 2,159 shares of the company’s stock valued at $80,000 after purchasing an additional 650 shares during the last quarter. Sanctuary Advisors LLC grew its stake in shares of Amphastar Pharmaceuticals by 8.5% during the 3rd quarter. Sanctuary Advisors LLC now owns 10,240 shares of the company’s stock valued at $466,000 after buying an additional 801 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Amphastar Pharmaceuticals by 8.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,195 shares of the company’s stock worth $379,000 after buying an additional 833 shares during the last quarter. 65.09% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently weighed in on AMPH shares. Piper Sandler reduced their target price on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a report on Friday, March 21st. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th.

Insider Activity at Amphastar Pharmaceuticals

In other news, CFO William J. Peters sold 4,231 shares of the stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the sale, the chief financial officer now owns 97,363 shares in the company, valued at approximately $2,681,377.02. This trade represents a 4.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 27.10% of the stock is owned by insiders.

Amphastar Pharmaceuticals Price Performance

Amphastar Pharmaceuticals stock opened at $23.93 on Wednesday. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The firm has a market capitalization of $1.14 billion, a P/E ratio of 7.98, a PEG ratio of 2.19 and a beta of 0.79. The firm has a fifty day moving average of $27.46 and a 200-day moving average of $36.97. Amphastar Pharmaceuticals, Inc. has a 52-week low of $22.64 and a 52-week high of $53.96.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.